The Shifting Sands of Science: A Year and a Half On, Federal Funding Cuts Continue to Reshape Research at Johns Hopkins

It's September 2026, and a palpable sense of unease still lingers across the labs and lecture halls of Johns Hopkins University. Roughly eighteen months have passed since the initial tremors of federal funding changes shook the institution, historically recognized by the United States National Science Foundation (NSF) for decades as the nation's leader in research and development expenditure. What began with an abrupt $800 million cut in United States Agency for International Development (USAID) grants in March 2025, leading to over 2200 job losses and scaled-back projects, has evolved into a persistent, unsettling shift in the very foundations of scientific inquiry.

The immediate fallout from those initial USAID cuts was, to put it mildly, brutal. But the troubles didn't end there. Now, as we look around, the situation continues to tighten. The NSF is reportedly set to issue its lowest number of new grants in four decades, signaling a stark reduction in available support. And it's not just about less money; it’s also about a fundamental reorientation in the types of research the government deems worthy of investment, coupled with a bewildering array of new rules proposed for grant approvals. "Even for the funding that exists, people are unsure what the rules are, and the rules are changed all the time," Brendon Davis, a PhD student in cell and molecular biology and former Vice President for Science Policy of Hopkins' Science Policy and Diplomacy Group, had observed earlier, a sentiment that sadly still rings true.

For researchers like Dr. Peter Winch, a Professor at the Bloomberg School of Public Health, the impact has been acutely personal and global. He previously recounted the painful loss of two crucial environmental sustainability projects in Bangladesh and the Democratic Republic of the Congo due to these funding shifts. Dr. Winch noted the frustrating reality of frequent rule changes under past administrations, which made long-term planning a nightmare. The ripple effect is undeniable: recent staff layoffs at Hopkins, and a growing struggle for graduate students to secure further jobs and funding for indirect costs – the essential, often unseen expenses of running a lab.

Beyond individual projects, there's a broader, existential threat to the research ecosystem itself, as Steven Salzberg has eloquently argued. He emphasizes the profound historical significance of federally funded research since the 1950s, a cornerstone of American innovation. But now, he worries about a chilling effect on international recruitment and collaboration. The perceived hostility towards non-native US citizens, he points out, isn't just bad optics; it actively discourages top talent from coming to Hopkins and the US, undermining the collaborative spirit that drives scientific breakthroughs.

Even in critical areas like cancer research, the effects are being felt. Dr. Elizabeth Jaffee, a faculty member diligently studying pancreatic cancer, highlighted how a pancreatic cancer vaccine developed by her team relies heavily on government funding. And then there are the unexpected hurdles: tariffs, for instance, added an extra $13,000 to the cost of a single vaccine lot arriving from Germany at the US border. Dr. Daniel Zabransky, a frequent collaborator with Dr. Jaffee, acknowledges that while cancer research isn't immune, fields like infectious diseases and global population health, especially those focusing on disparities, often bear the brunt of changes in priorities and policies more directly. Yet, he concedes, structural changes at the NIH and other government funders are making things harder for everyone, across the board.

Some projects, once halted, simply cease to exist. Radha Rajan, a researcher at the Johns Hopkins Center for Communication Programs, confirmed via email that the Breakthrough ACTION project – an initiative focused on implementing vital health knowledge – was stopped and, regrettably, never reinstated. It's a stark reminder of the long-term consequences these funding shifts can have on real-world health interventions.

Jeff Coller, a Bloomberg Distinguished Professor immersed in RNA research, continues to voice concerns about the potential loss of international competitiveness. The struggle to recruit top-tier graduate students, he notes, is a significant worry. While Hopkins has bravely responded with internal "resilience funds" to help protect its faculty and their vital work, it's a testament to the fact that this isn't just a federal problem; it's a deeply felt local challenge demanding innovative, institutional responses.

As the academic year progresses into late 2026, the situation remains tense and continually evolving. The legacy of federal funding changes casts a long shadow over Johns Hopkins' research endeavors, forcing adaptation, resilience, and a renewed conversation about the true value and sustainability of scientific discovery.